Fibroblast Growth Factor 21 Drives Dynamics of Local and Systemic Stress Responses in Mitochondrial Myopathy with mtDNA Deletions
: Forsström Saara, Jackson Christopher B, Carroll Christopher J, Kuronen Mervi, Pirinen Eija, Pradhan Swagat, Marmyleva Anastasiia, Auranen Mari, Kleine Iida-Marja, Khan Nahid A, Roivainen Anne, Marjamäki Päivi, Liljenbäck Heidi, Wang Liya, Battersby Brendan J, Richter Uwe, Velagapudi Vidya, Nikkanen Joni, Euro Liliya, Suomalainen Anu
Publisher: Elsevier Inc
: 2019
: Cell Metabolism
: 30
: 6
: 1040
: 1054.e7
DOI: https://doi.org/10.1016/j.cmet.2019.08.019
: https://research.utu.fi/converis/portal/detail/Publication/43686508
Abstract
Mitochondrial dysfunction elicits stress responses that safeguard cellular homeostasis against metabolic insults. Mitochondrial integrated stress response (ISRmt) is a major response to mitochondrial (mt)DNA expression stress (mtDNA maintenance, translation defects), but the knowledge of dynamics or interdependence of components is lacking. We report that in mitochondrial myopathy, ISRmt progresses in temporal stages and development from early to chronic and is regulated by autocrine and endocrine effects of FGF21, a metabolic hormone with pleiotropic effects. Initial disease signs induce transcriptional ISRmt (ATF5, mitochondrial one-carbon cycle, FGF21, and GDF15). The local progression to 2nd metabolic ISRmt stage (ATF3, ATF4, glucose uptake, serine biosynthesis, and transsulfuration) is FGF21 dependent. Mitochondrial unfolded protein response marks the 3rd ISRmt stage of failing tissue. Systemically, FGF21 drives weight loss and glucose preference, and modifies metabolism and respiratory chain deficiency in a specific hippocampal brain region. Our evidence indicates that FGF21 is a local and systemic messenger of mtDNA stress in mice and humans with mitochondrial disease.